Vanda Pharmaceuticals Announces US Commercial Availability of NEREUS (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

Vanda Pharmaceuticals Announces US Commercial Availability of NEREUS (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

Consumers can now order NEREUS instantly at nereus.us WASHINGTON, May 1, 2026 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) at present introduced that NEREUS (tradipitant) is now commercially obtainable throughout the United States for the prevention of vomiting induced by movement in adults, marking the first new prescription drugs authorised for this situation in…

Read Full News
Crispr gene editing treatment from Intellia succeeds in Phase 3 trial

Crispr gene editing treatment from Intellia succeeds in Phase 3 trial

Intellia Therapeutics, constructing exterior and firm signal, Cambridge, Massachusetts, USA. Spencer Grant | Universal Images Group | Getty Images Intellia Therapeutics stated its Crispr-based treatment for a uncommon swelling situation met its objectives in a late-stage trial, marking a milestone for the sector of gene editing and placing the corporate on monitor to hunt approval…

Read Full News